Omnicell Reports Strong Q4 2025 Earnings and Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Should l Buy OMCL?
Source: seekingalpha
- Strong Financial Performance: Omnicell reported total revenue of $314 million for Q4 2025, reflecting a 2% increase from Q4 2024, indicating sustained demand and solid execution in the medication management sector.
- Annual Recurring Revenue Growth: The company exited 2025 with an annual recurring revenue (ARR) of $636 million, a 10% increase year-over-year, showcasing strong customer demand for new products, particularly Titan XT and the OmniSphere platform.
- Optimistic Outlook: Management expects total revenue for Q1 2026 to be between $300 million and $310 million, with full-year revenue projected at $1.215 billion to $1.255 billion, demonstrating confidence in future market conditions.
- Enhanced Market Competitiveness: The successful launch of Titan XT and positive market feedback are expected to drive market share growth in medication management, especially with a replacement cycle opportunity exceeding $2.5 billion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OMCL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OMCL
Wall Street analysts forecast OMCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMCL is 54.20 USD with a low forecast of 46.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 39.080
Low
46.00
Averages
54.20
High
63.00
Current: 39.080
Low
46.00
Averages
54.20
High
63.00
About OMCL
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Omnicell Reports Strong Q4 2025 Earnings and Outlook
- Strong Financial Performance: Omnicell reported total revenue of $314 million for Q4 2025, reflecting a 2% increase from Q4 2024, indicating sustained demand and solid execution in the medication management sector.
- Annual Recurring Revenue Growth: The company exited 2025 with an annual recurring revenue (ARR) of $636 million, a 10% increase year-over-year, showcasing strong customer demand for new products, particularly Titan XT and the OmniSphere platform.
- Optimistic Outlook: Management expects total revenue for Q1 2026 to be between $300 million and $310 million, with full-year revenue projected at $1.215 billion to $1.255 billion, demonstrating confidence in future market conditions.
- Enhanced Market Competitiveness: The successful launch of Titan XT and positive market feedback are expected to drive market share growth in medication management, especially with a replacement cycle opportunity exceeding $2.5 billion.
See More
Omnicell Q4 Earnings Report Analysis
- Earnings Performance: Omnicell reported a Q4 non-GAAP EPS of $0.40, missing estimates by $0.10, indicating pressure on profitability, while revenue of $314 million, up 2.3% year-over-year, slightly exceeded market expectations by $640,000, reflecting the company's stability in the market.
- Declining EBITDA: The non-GAAP EBITDA for Q4 2025 was $37 million, down from $46 million in Q4 2024, suggesting challenges in cost control and profitability that may impact future investor confidence and stock performance.
- Drop in Product Bookings: As of December 31, 2025, Omnicell's product bookings were $535 million, a 4% year-over-year decline primarily due to the late stage of the XT upgrade cycle, indicating weakening market demand that could affect future revenue growth.
- 2026 Guidance: Omnicell's guidance for 2026 indicates expected product bookings between $510 million and $560 million and annual recurring revenue between $680 million and $700 million, although overall revenue expectations exceed market consensus, ongoing market conditions will need to be monitored for their potential impact on performance.
See More
Omnicell Reports Strong Q4 2025 Financial Results and Launches Titan XT
- Strong Financial Performance: Omnicell reported total revenues of $314 million for Q4 2025, a 2% increase from Q4 2024, driven by robust technical service and SaaS revenues, indicating the company's sustained growth potential in medication management.
- Annual Revenue Growth: The total revenue for the year 2025 reached $1.185 billion, up 7% year-over-year, reflecting strong demand for connected devices and technical services, which underscores the company's solid market position and confidence in future growth.
- New Product Launch: At the 2025 ASHP meeting, Omnicell unveiled Titan XT, aimed at enhancing medication management efficiency by integrating automation with intelligent technology, expected to strengthen the company's competitive edge in healthcare systems to meet rising market demands.
- Positive Future Outlook: The company anticipates total revenues for 2026 to range between $1.215 billion and $1.255 billion, demonstrating confidence in future growth while planning to achieve sustainable profitability through ongoing innovation and market expansion.
See More
Bank of America Upgrades Omnicell to Buy with Price Target Increase
- Rating Upgrade: Bank of America upgraded Omnicell (OMCL) from Neutral to Buy and raised its price target from $53 to $70, indicating analyst optimism ahead of the company's Q4 2025 results.
- Market Leadership: Omnicell dominates the market for automated dispensing cabinets in hospitals, and analyst Allen Lutz noted the launch of its first new cabinet since 2017, which could further solidify its market position.
- Revenue Growth Outlook: Although the analyst projects a 3%-4% CAGR in connected device revenue through 2028, this is still indicative of the company's potential for future growth compared to mid-teens growth in the previous cycle.
- Investment Opportunity: The analyst believes that Omnicell's initial 2026 guidance may only reflect modest contributions in the second half of this year, viewing any weakness as a buying opportunity, which demonstrates confidence in the company's long-term growth trajectory.
See More
Omnicell Scheduled to Announce Q4 Earnings on February 5th
- Earnings Announcement: Omnicell (OMCL) is set to announce its Q4 earnings on February 5th before market open, with consensus EPS estimate at $0.50, reflecting a 16.7% year-over-year decline, while revenue is expected to reach $313.36 million, a 2.1% increase year-over-year, which could significantly impact investor sentiment.
- Strong Historical Performance: Over the past two years, Omnicell has consistently beaten both EPS and revenue estimates 100% of the time, demonstrating robust financial stability and market adaptability, which may attract increased investor interest in its future performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen three upward revisions and one downward revision, while revenue estimates have also experienced three upward and one downward revision, indicating some market divergence in expectations that could affect stock price volatility.
- Platform Impact: The recent launch of Omnicell's Titan XT enterprise platform is expected to significantly enhance pharmacy operational efficiency, thereby strengthening the company's competitive position in the healthcare technology sector and further solidifying its market presence.
See More
Latest Wall Street Rating Updates
- AMD Rating Reaffirmed: Barclays reiterates its overweight rating on AMD, citing the company's growing share in the PC and server markets, alongside significant spending potential from clients like OpenAI, indicating strong future growth in AI.
- Airbnb Upgrade: Citizens upgrades Airbnb from market perform to market outperform with a price target of $160, anticipating multiple upcoming catalysts that could drive the stock beyond current expectations.
- GE Vernova Rating Recovery: Baird upgrades GE Vernova from neutral to outperform, asserting that concerns about capacity are overblown and that the energy infrastructure cycle is still in its early stages, positioning GE Vernova as a key beneficiary.
- Broadridge Financial Upgrade: DA Davidson raises Broadridge's rating from hold to buy, arguing that the recent 30% decline in shares presents a buying opportunity, maintaining a price target of $228 as the sell-off is seen as excessive.
See More
Omnicell Reports Strong Q4 2025 Earnings and Outlook
- Strong Financial Performance: Omnicell reported total revenue of $314 million for Q4 2025, reflecting a 2% increase from Q4 2024, indicating sustained demand and solid execution in the medication management sector.
- Annual Recurring Revenue Growth: The company exited 2025 with an annual recurring revenue (ARR) of $636 million, a 10% increase year-over-year, showcasing strong customer demand for new products, particularly Titan XT and the OmniSphere platform.
- Optimistic Outlook: Management expects total revenue for Q1 2026 to be between $300 million and $310 million, with full-year revenue projected at $1.215 billion to $1.255 billion, demonstrating confidence in future market conditions.
- Enhanced Market Competitiveness: The successful launch of Titan XT and positive market feedback are expected to drive market share growth in medication management, especially with a replacement cycle opportunity exceeding $2.5 billion.
See More
Omnicell Q4 Earnings Report Analysis
- Earnings Performance: Omnicell reported a Q4 non-GAAP EPS of $0.40, missing estimates by $0.10, indicating pressure on profitability, while revenue of $314 million, up 2.3% year-over-year, slightly exceeded market expectations by $640,000, reflecting the company's stability in the market.
- Declining EBITDA: The non-GAAP EBITDA for Q4 2025 was $37 million, down from $46 million in Q4 2024, suggesting challenges in cost control and profitability that may impact future investor confidence and stock performance.
- Drop in Product Bookings: As of December 31, 2025, Omnicell's product bookings were $535 million, a 4% year-over-year decline primarily due to the late stage of the XT upgrade cycle, indicating weakening market demand that could affect future revenue growth.
- 2026 Guidance: Omnicell's guidance for 2026 indicates expected product bookings between $510 million and $560 million and annual recurring revenue between $680 million and $700 million, although overall revenue expectations exceed market consensus, ongoing market conditions will need to be monitored for their potential impact on performance.
See More
Omnicell Reports Strong Q4 2025 Financial Results and Launches Titan XT
- Strong Financial Performance: Omnicell reported total revenues of $314 million for Q4 2025, a 2% increase from Q4 2024, driven by robust technical service and SaaS revenues, indicating the company's sustained growth potential in medication management.
- Annual Revenue Growth: The total revenue for the year 2025 reached $1.185 billion, up 7% year-over-year, reflecting strong demand for connected devices and technical services, which underscores the company's solid market position and confidence in future growth.
- New Product Launch: At the 2025 ASHP meeting, Omnicell unveiled Titan XT, aimed at enhancing medication management efficiency by integrating automation with intelligent technology, expected to strengthen the company's competitive edge in healthcare systems to meet rising market demands.
- Positive Future Outlook: The company anticipates total revenues for 2026 to range between $1.215 billion and $1.255 billion, demonstrating confidence in future growth while planning to achieve sustainable profitability through ongoing innovation and market expansion.
See More
Bank of America Upgrades Omnicell to Buy with Price Target Increase
- Rating Upgrade: Bank of America upgraded Omnicell (OMCL) from Neutral to Buy and raised its price target from $53 to $70, indicating analyst optimism ahead of the company's Q4 2025 results.
- Market Leadership: Omnicell dominates the market for automated dispensing cabinets in hospitals, and analyst Allen Lutz noted the launch of its first new cabinet since 2017, which could further solidify its market position.
- Revenue Growth Outlook: Although the analyst projects a 3%-4% CAGR in connected device revenue through 2028, this is still indicative of the company's potential for future growth compared to mid-teens growth in the previous cycle.
- Investment Opportunity: The analyst believes that Omnicell's initial 2026 guidance may only reflect modest contributions in the second half of this year, viewing any weakness as a buying opportunity, which demonstrates confidence in the company's long-term growth trajectory.
See More
Omnicell Scheduled to Announce Q4 Earnings on February 5th
- Earnings Announcement: Omnicell (OMCL) is set to announce its Q4 earnings on February 5th before market open, with consensus EPS estimate at $0.50, reflecting a 16.7% year-over-year decline, while revenue is expected to reach $313.36 million, a 2.1% increase year-over-year, which could significantly impact investor sentiment.
- Strong Historical Performance: Over the past two years, Omnicell has consistently beaten both EPS and revenue estimates 100% of the time, demonstrating robust financial stability and market adaptability, which may attract increased investor interest in its future performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen three upward revisions and one downward revision, while revenue estimates have also experienced three upward and one downward revision, indicating some market divergence in expectations that could affect stock price volatility.
- Platform Impact: The recent launch of Omnicell's Titan XT enterprise platform is expected to significantly enhance pharmacy operational efficiency, thereby strengthening the company's competitive position in the healthcare technology sector and further solidifying its market presence.
See More
Latest Wall Street Rating Updates
- AMD Rating Reaffirmed: Barclays reiterates its overweight rating on AMD, citing the company's growing share in the PC and server markets, alongside significant spending potential from clients like OpenAI, indicating strong future growth in AI.
- Airbnb Upgrade: Citizens upgrades Airbnb from market perform to market outperform with a price target of $160, anticipating multiple upcoming catalysts that could drive the stock beyond current expectations.
- GE Vernova Rating Recovery: Baird upgrades GE Vernova from neutral to outperform, asserting that concerns about capacity are overblown and that the energy infrastructure cycle is still in its early stages, positioning GE Vernova as a key beneficiary.
- Broadridge Financial Upgrade: DA Davidson raises Broadridge's rating from hold to buy, arguing that the recent 30% decline in shares presents a buying opportunity, maintaining a price target of $228 as the sell-off is seen as excessive.
See More
